KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Evolent Health (EVH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to 5.76%.

  • Evolent Health's EBITDA Margin fell 7300.0% to 5.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.86%, marking a year-over-year decrease of 46200.0%. This contributed to the annual value of 3.68% for FY2024, which is 35700.0% up from last year.
  • Evolent Health's EBITDA Margin amounted to 5.76% in Q3 2025, which was down 7300.0% from 11.49% recorded in Q2 2025.
  • In the past 5 years, Evolent Health's EBITDA Margin registered a high of 0.53% during Q3 2022, and its lowest value of 14.93% during Q1 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 4.79% (2024), whereas its average is 5.19%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 895300bps in 2021, then tumbled by -109800bps in 2025.
  • Quarter analysis of 5 years shows Evolent Health's EBITDA Margin stood at 2.27% in 2021, then plummeted by -32bps to 3.0% in 2022, then tumbled by -148bps to 7.44% in 2023, then surged by 36bps to 4.79% in 2024, then fell by -20bps to 5.76% in 2025.
  • Its EBITDA Margin was 5.76% in Q3 2025, compared to 11.49% in Q2 2025 and 14.93% in Q1 2025.